{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:00:03Z","timestamp":1789758003576,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["EQU201903007852"],"award-info":[{"award-number":["EQU201903007852"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003100","name":"F\u00e9d\u00e9ration Fran\u00e7aise de Cardiologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003100","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00392-024-02462-x","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T17:38:51Z","timestamp":1716917931000},"page":"1263-1273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Adverse myocardial and vascular side effects of immune checkpoint inhibitors: a prospective multimodal cardiovascular assessment"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-8896","authenticated-orcid":false,"given":"Mariana","family":"Mirabel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assi\u00e9","family":"Eslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Mousseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Wahbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloi","family":"Marijon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Villefaillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Fayol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Agn\u00e8s","family":"Dragon-Durey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s Lillo","family":"Le Louet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Soulat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean S\u00e9bastien","family":"Hulot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"2462_CR1","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","volume":"5","author":"SL Topalian","year":"2019","unstructured":"Topalian SL et al (2019) Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non\u2013small cell lung cancer treated with nivolumab. JAMA Oncol 5:1411","journal-title":"JAMA Oncol"},{"key":"2462_CR2","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V (2019) Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2:e192535","journal-title":"JAMA Netw Open"},{"key":"2462_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J et al (2022) Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 387:217\u2013226","journal-title":"N Engl J Med"},{"key":"2462_CR4","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749\u20131755","journal-title":"N Engl J Med"},{"key":"2462_CR5","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"J-E Salem","year":"2018","unstructured":"Salem J-E et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579\u20131589","journal-title":"Lancet Oncol"},{"key":"2462_CR6","doi-asserted-by":"publisher","unstructured":"Drobni ZD et al (2020) Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation Circulationaha 120.049981. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.049981","DOI":"10.1161\/CIRCULATIONAHA.120.049981"},{"key":"2462_CR7","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/JCO.21.01808","volume":"40","author":"D Laenens","year":"2022","unstructured":"Laenens D et al (2022) Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. JCO 40:3430\u20133438","journal-title":"JCO"},{"key":"2462_CR8","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721","journal-title":"JAMA Oncol"},{"key":"2462_CR9","doi-asserted-by":"publisher","unstructured":"Lyon AR et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J ehac244. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"2462_CR10","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129\u20132200","journal-title":"Eur Heart J"},{"key":"2462_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP et al (2019) Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 140:80\u201391","journal-title":"Circulation"},{"key":"2462_CR12","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Y Adler","year":"2015","unstructured":"Adler Y et al (2015) 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36:2921\u20132694","journal-title":"Eur Heart J"},{"key":"2462_CR13","doi-asserted-by":"publisher","unstructured":"Addison D et al (2023) Cardiovascular imaging in contemporary cardio-oncology: a scientific statement from the American Heart Association. Circulation CIR.0000000000001174. https:\/\/doi.org\/10.1161\/CIR.0000000000001174","DOI":"10.1161\/CIR.0000000000001174"},{"key":"2462_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J et al (2022) Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 43:280\u2013299","journal-title":"Eur Heart J"},{"key":"2462_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5012","author":"B Shankar","year":"2020","unstructured":"Shankar B et al (2020) Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non\u2013small cell lung cancer. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2020.5012","journal-title":"JAMA Oncol"},{"key":"2462_CR16","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/heartjnl-2019-316297","volume":"106","author":"J Lambert","year":"2020","unstructured":"Lambert J et al (2020) Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity. Heart 106:817\u2013823","journal-title":"Heart"},{"key":"2462_CR17","first-page":"e009214","volume":"12","author":"AN Bhuva","year":"2019","unstructured":"Bhuva AN et al (2019) A Multicenter, Scan-rescan, human and machine learning CMR study to test generalizability and precision in imaging biomarker analysis. Circ: Cardiovasc Imaging 12:e009214","journal-title":"Circ: Cardiovasc Imaging"},{"key":"2462_CR18","first-page":"673","volume":"4","author":"Y Tamura","year":"2022","unstructured":"Tamura Y et al (2022) Longitudinal strain and troponin I elevation in patients undergoing immune checkpoint inhibitor therapy. JACC: CardioOncology 4:673\u2013685","journal-title":"JACC: CardioOncology"},{"key":"2462_CR19","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am College Cardiol 71:1755\u20131764","journal-title":"J Am College Cardiol"},{"key":"2462_CR20","doi-asserted-by":"publisher","first-page":"e029211","DOI":"10.1161\/JAHA.122.029211","volume":"12","author":"F Deharo","year":"2023","unstructured":"Deharo F et al (2023) Diagnostic value of the international society of cardio-oncology definition for suspected immune checkpoint inhibitor\u2013associated myocarditis. JAHA 12:e029211","journal-title":"JAHA"},{"key":"2462_CR21","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","volume":"72","author":"VM Ferreira","year":"2018","unstructured":"Ferreira VM et al (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation. J Am College Cardiol 72:3158\u20133176","journal-title":"J Am College Cardiol"},{"key":"2462_CR22","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P et al (2021) Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor\u2013associated myocarditis. J Am College Cardiol 77:1503\u20131516","journal-title":"J Am College Cardiol"},{"key":"2462_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jacc.2021.11.048","volume":"79","author":"JT Vuong","year":"2022","unstructured":"Vuong JT et al (2022) Immune checkpoint therapies and atherosclerosis: mechanisms and clinical implications. J Am College Cardiol 79:577\u2013593","journal-title":"J Am College Cardiol"},{"key":"2462_CR24","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"J-E Salem","year":"2019","unstructured":"Salem J-E et al (2019) Abatacept for severe immune checkpoint inhibitor\u2013associated myocarditis. N Engl J Med 380:2377\u20132379","journal-title":"N Engl J Med"},{"key":"2462_CR25","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1148\/radiol.2021210814","volume":"301","author":"A Faron","year":"2021","unstructured":"Faron A et al (2021) Cardiac MRI Depicts Immune checkpoint inhibitor\u2013induced myocarditis: a prospective study. Radiology 301:602\u2013609","journal-title":"Radiology"},{"key":"2462_CR26","first-page":"137","volume":"3","author":"S Waliany","year":"2021","unstructured":"Waliany S et al (2021) Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors. JACC: CardioOncology 3:137\u2013139","journal-title":"JACC: CardioOncology"},{"key":"2462_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy485","author":"C Thibault","year":"2018","unstructured":"Thibault C, Vano Y, Soulat G, Mirabel M (2018) Immune checkpoint inhibitors myocarditis: not all cases are clinically patent. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehy485","journal-title":"Eur Heart J"},{"key":"2462_CR28","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C et al (2020) Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 6:865","journal-title":"JAMA Oncol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02462-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-024-02462-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02462-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T18:19:32Z","timestamp":1721845172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-024-02462-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2462"],"URL":"https:\/\/doi.org\/10.1007\/s00392-024-02462-x","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}